PMID- 19139888
OWN - NLM
STAT- MEDLINE
DCOM- 20090612
LR  - 20211028
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 58
IP  - 8
DP  - 2009 Aug
TI  - Antigen loading of DCs with irradiated apoptotic tumor cells induces improved 
      anti-tumor immunity compared to other approaches.
PG  - 1257-64
LID - 10.1007/s00262-008-0638-7 [doi]
AB  - Dendritic cells (DCs) serve as central regulators of adaptive immunity by 
      presenting antigens and providing necessary co-signals. Environmental information 
      received by the DCs determines the co-signals delivered to the responding 
      adaptive cells and, ultimately, the outcome of the interaction. DCs loaded with 
      relevant antigens have been used as therapeutic cellular vaccines, but the 
      optimal antigen loading method has not been determined. We compared different 
      methods to load class I and class II epitopes from the male antigenic complex, 
      HY, onto DCs for the potency of the immune response induced in vivo. 
      Co-incubation of female DCs with HY peptides, RNA or cell lysate from HY 
      expressing tumor induced immune responses equivalent to male DCs. In contrast, 
      female DCs incubated with irradiated, apoptotic HY expressing tumor cells (or 
      male B cells) generated a stronger immune response than male DCs or female DCs 
      loaded using any of the other methods. DC loading with apoptotic tumor resulted 
      in complete protection against high dose HY-expressing tumor challenge whereas 
      100% lethality was observed in groups receiving DCs that were loaded with 
      peptides, RNA, or lysate. We conclude that signals provided to the DCs by 
      apoptotic cells substantially augment the potency of DC vaccines.
FAU - Fry, Terry J
AU  - Fry TJ
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer 
      Institute/National Institutes of Health, Bethesda, MD 20892, USA. 
      fryt@mail.nih.gov
FAU - Shand, Jessica L
AU  - Shand JL
FAU - Milliron, Matthew
AU  - Milliron M
FAU - Tasian, Sarah K
AU  - Tasian SK
FAU - Mackall, Crystal L
AU  - Mackall CL
LA  - eng
GR  - T32 HD044331/HD/NICHD NIH HHS/United States
GR  - Z99 CA999999/ImNIH/Intramural NIH HHS/United States
GR  - HHMI/Howard Hughes Medical Institute/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20090113
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Cancer Vaccines)
RN  - 0 (H-Y Antigen)
RN  - 187348-17-0 (Interleukin-12)
SB  - IM
MH  - Animals
MH  - *Antigen Presentation
MH  - Apoptosis
MH  - CD4-Positive T-Lymphocytes/immunology/metabolism
MH  - CD8-Positive T-Lymphocytes/immunology/metabolism
MH  - Cancer Vaccines/*immunology/therapeutic use
MH  - Carcinoma/*immunology/therapy
MH  - Cell Line, Tumor
MH  - Dendritic Cells/*immunology/transplantation
MH  - Female
MH  - H-Y Antigen/*immunology
MH  - *Immunotherapy, Adoptive
MH  - Interleukin-12/immunology/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Urinary Bladder Neoplasms/*immunology/therapy
PMC - PMC2791794
MID - NIHMS161683
EDAT- 2009/01/14 09:00
MHDA- 2009/06/13 09:00
PMCR- 2009/01/13
CRDT- 2009/01/14 09:00
PHST- 2008/05/22 00:00 [received]
PHST- 2008/12/01 00:00 [accepted]
PHST- 2009/01/14 09:00 [entrez]
PHST- 2009/01/14 09:00 [pubmed]
PHST- 2009/06/13 09:00 [medline]
PHST- 2009/01/13 00:00 [pmc-release]
AID - 638 [pii]
AID - 10.1007/s00262-008-0638-7 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2009 Aug;58(8):1257-64. doi: 
      10.1007/s00262-008-0638-7. Epub 2009 Jan 13.